Biosergen publishes interim report for third quarter 2022
Wednesday, November 30, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net
Summary of the Interim Report for Q3 2022
| 2022 | 2021 | 2022 | 2021 | 2021 | ||
| TSEK | July-Sep | July-Sep | Jan-Sep | Jan-Sep | Jan-Dec | |
| Other income | 493 | 2.652 | 3.219 | 4.653 | 8.573 | |
| Profit/loss before depreciation (EBITDA) | -14.515 | -6.404 | -27.496 | -24.202 | -34.077 | |
| Operating profit/loss befor net financials | -14.515 | -6.404 | -27.496 | -24.202 | -34.077 | |
| Netprofit/loss for the period | -14.499 | -6.550 | -27.474 | -24.359 | -34.318 | |
| Earnings per share (SEK) | -0,51 | -0,40 | -0,97 | -1,51 | -1,22 | |
Highlights during Q3 2022
- August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
- August 31, Biosergen receives a loan of SEK 7 million to finance continued development
- September 2, Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
- September 8, Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study
Highlights after the period
- October 4, Biosergen announces the outcome in the rights issue
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net
Certified Adviser
Erik Penser Bank
Telefon: +46 8 463 800
E-mail: certifiedadvisor@penser.se
This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 30, 2022.
ABOUT BIOSERGEN
Biosergen is a clinical stage biotechnology company that employs all its organizational and financial resources on the clinical development of BSG005. BSG005, a polyene macrolide, is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, and being completely free of the kidney toxicity hampering other drugs in its class. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States.